BEIJING--(BUSINESS WIRE)--China Medical Technologies, Inc. (the “Company”) (NASDAQ: CMED), a leading China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostic systems and high intensity focused ultrasound products, today announced that it has completed the development of 10 new enhanced chemiluminescence immunoassay (“ECLIA”) infertility diagnostic reagents, increasing the Company’s reagent kit offering to a total of 72. China Medical expects to introduce these new reagents in July 2007.
